Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2021-02-03 Regulatory Filings
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated February 3, 2021, announcing that bioMérieux has received the CE mark for its NEPHROCHECK® test. It details the product's function, scientific basis (biomarkers TIMP-2 and IGFBP-7), quotes management, and discusses availability. This type of announcement, which releases key operational and product news to the public and investors, is best classified as an Earnings Release (ER) if it were tied to financial results, but since it is a specific product/regulatory milestone announcement that doesn't fit the other categories well (it's not a full report, transcript, or management change), it falls under the general category for significant corporate news that isn't strictly financial reporting or a formal regulatory filing like a 10-K or DVA. However, given the options, this is a high-level corporate announcement. It is not a Call Transcript (CT), a formal 10-K, or an Interim Report (IR). It is a specific announcement of a regulatory achievement (CE mark) and product launch. Since there is no specific category for 'Product Launch Announcement' or 'Regulatory Approval Announcement' (other than the general RNS), and it is not a short announcement pointing to a larger document (RPA), it is most appropriately classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were part of a quarterly cycle, but it reads like a standalone press release. Given the context of financial reporting databases, standalone press releases announcing significant operational milestones often default to RNS if a more specific category like ER (which usually focuses on financial performance metrics) is not applicable. Since this is a positive operational/regulatory update, RNS is the most suitable fallback.
2021-02-03 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as mandated by French commercial code and AMF regulations. This type of filing, which reports on share structure and voting rights, is most closely aligned with regulatory reporting concerning share capital changes or ownership notifications. Given the specific nature of reporting total voting rights monthly, it fits best under the general category of regulatory filings that track ownership/capital structure changes, but none of the specific codes perfectly match a 'Monthly Voting Rights Report'. However, the content is a direct regulatory disclosure about the number of shares and voting rights as of a specific date (31/12/2020), which is a key component of capital structure reporting. Since there is no specific code for 'Monthly Voting Rights Report', and it is a direct regulatory disclosure, it falls under the general 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA). Given the context of French regulatory filings, these monthly voting rights reports are standard disclosures. Since it is not a dividend notice (DIV), director dealing (DIRS), or major shareholding notification (MRQ) about a specific shareholder crossing a threshold, but rather a comprehensive statement of the total, RNS is the most appropriate fallback for a standard, recurring regulatory disclosure that doesn't fit a more specific capital event code. The document length (2161 chars) is short, but it is the report itself, not an announcement of a report, so RPA is not applicable. I will classify it as RNS as it is a mandatory regulatory filing that doesn't fit the other specific codes.
2021-01-08 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated December 16, 2020, announcing that bioMérieux has received CE marking for a new molecular biology test (SARS-COV-2 RESPI R-GENE®). It details the product features, provides quotes from management, and includes standard 'About Us' and 'Contact' sections typical of corporate news releases. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). It is a specific announcement regarding a product development/regulatory milestone. Since it is a general corporate announcement that doesn't fit the specific categories like DIV, CAP, or MANG, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or corporate news announcements that aren't covered elsewhere.
2020-12-16 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from bioMérieux announcing a new CE-marked molecular diagnostic test (SARS-COV-2 RESPI R-GENE®). It details the product features, clinical relevance, and availability. This type of announcement, focusing on a specific product development, regulatory clearance, or general corporate news that isn't a mandatory periodic financial filing (like 10-K or IR) or a specific shareholder action (like DIV or DVA), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report, earnings release (ER), or a specific capital/legal update, the most appropriate general category for a significant, non-financial corporate announcement is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory/news disclosures.
2020-12-16 French
Inside Information / Other news releases
Earnings Release Classification · 98% confidence The document is a press release dated December 14, 2020, announcing an 'Increased outlook for full-year 2020' and providing specific updated financial guidance (net sales and operating income). This content—the initial announcement of key financial results/updates for a period—fits the definition of an Earnings Release (ER). It is not a full Annual Report (10-K), an Interim Report (IR), or a transcript (CT). It is a direct release of financial performance highlights, not just an announcement that a report is coming (RPA). FY 2020
2020-12-14 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release dated December 14, 2020, announcing an upward revision ('Relèvement') of the 2020 financial outlook (revenue growth and operating income). It provides key financial highlights for the period and includes a financial calendar pointing to the full annual results release date (February 24, 2021). This structure—a brief, high-level announcement of preliminary or updated results before the full official filing—is characteristic of an Earnings Release (ER). It is not the full Annual Report (10-K) or the comprehensive Interim Report (IR), nor is it merely an announcement of a report's publication (RPA), as it contains the actual updated figures. The document is short (4407 chars) but delivers the core earnings update. FY 2020
2020-12-14 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.